home / stock / obsv / obsv news

OBSV News and Press, ObsEva SA From 12/23/19

Stock Information
Company Name: ObsEva SA
Stock Symbol: OBSV
Market: NASDAQ
Website: obseva.com
Menu
OBSV OBSV Quote OBSV Short OBSV News OBSV Articles OBSV Message Board
Get OBSV Alerts

News, Short Squeeze, Breakout and More Instantly...
OBSV - SDRL, ITCI, IDRA and OTLK among midday movers

Gainers: Intra-Cellular Therapies (NASDAQ: ITCI )  +204% . More news on: Intra-Cellular Therapies, Inc., Cassava Sciences, Inc., Microbot Medical Inc., Stocks on the move, Read more ...

OBSV - CAG, RAD among premarket gainers

Paratek Pharmaceuticals (NASDAQ: PRTK )  +45%  on BARDA contract  for Nuzyra. More news on: Paratek Pharmaceuticals, Inc., Rite Aid Corporation, Catalyst Biosciences, Inc., Stocks on the move, Read more ...

OBSV - MU, PCG, GDOT and DERM among after hour movers

Gainers: REVG   +6.9% . MU   +3.4% . PCG   +2.2% . OBSV   +2.8% . DERM   +1.1% . More news on: REV Group, Inc., Micron Technology, Inc., PG&E Corporation, Stocks on the move, , News on ETFs Read more ...

OBSV - FDX, CTAS, PACB and SCS among after hour movers

Gainers: ASLN   +8.6% . NK   +7.1% . SCS   +5.5% . OBSV   +2.8% . CTAS   +2.8% . More news on: ASLAN Pharmaceuticals Limited, NantKwest, Inc., Steelcase Inc., Stocks on the move, , News on ETFs Read more ...

OBSV - MDB, GNW among premarket gainer

Technical Communications (NASDAQ: TCCO ) +260%  after Q4 results . More news on: Technical Communications Corporation, Equillium, Inc., CounterPath Corporation, Stocks on the move, Read more ...

OBSV - AR, ARQL, MBIO and DPLO among midday movers

Gainers: Synthorx (NASDAQ: THOR )  +170% . More news on: Synthorx, Inc., ArQule, Inc., Forty Seven, Inc., Stocks on the move, Read more ...

OBSV - BLUE, PCG among premarket gainers

Synthorx (NASDAQ: THOR ) +169%  on being acquired by Sanofi. More news on: Synthorx, Inc., XBiotech Inc., ArQule, Inc., Stocks on the move, Read more ...

OBSV - ObsEva up 26% premarket on positive data on linzagolix

ObsEva SA (NASDAQ: OBSV ) is up  26%  premarket on the heels of positive results from a Phase 3 PRIMROSE 2 trial evaluating linzagolix, including 100 mg and 200 mg doses, both with and without hormonal add-back therapy (ABT) for the treatment of heavy menstrual bleeding...

OBSV - ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix

Phase 3 trial (PRIMROSE 2) met primary and secondary efficacy endpoints 93.9% responder rate for 200 mg with ABT (p < 0.001) 56.7% responder rate for 100 mg without ABT (p < 0.001) Both doses achieved important clinically relevant secondary endpoints including amenorrhea (p &l...

OBSV - My 20/20 Vision For The Year 2020

The following list reflects actual dividend paying stocks that I hold in my personal portfolio: Barings BDC, Inc. ( BBDC ), BlackRock Capital Investment ( BKCC ), Blueknight Energy Partners - PFD Units ( BKEPP ), BlackRock Income Trust ( BKT ), BlackRock Enhanced Equity Dividend Trust ( BDJ ),...
Previous 10 Next 10